Manchester, United Kingdom
Oxyrane, founded in 2007, is a biopharmaceutical company based in the United Kingdom. Operating within the Biopharma, Biotechnology, and Pharmaceutical industries, Oxyrane focuses on developing innovative solutions in the biotech space.
The company’s last known funding event was a $26.50M Series D investment, secured on November 17, 2011. This funding round involved participation from notable investment firms including Forbion, New Science Ventures, and Morningside Group.
Though currently there is limited publicly available information regarding its recent developments or business advancements, Oxyrane's sustained backing from distinguished investors highlights a promising potential within their targeted sectors. Their strong financial history suggests a well-supported endeavor toward significant innovations in pharmaceutical and biotechnological advancements.
